Decierdo, Josella G.
HRN: 21-32-21 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/09/2022
CO-AMOXICLAV 625MG (TAB)
05/09/2022
05/15/2022
ORAL
625mg/tab
BID
S/P NSVD With Second Degree Laceration
Waiting Final Action
Indication: Prophylaxis Type of Infection: Reproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes